| The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four research networks that form the NHLBI Family Blood Pressure Program (FBPP). Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. Participants include non-Hispanic White Americans from Rochester, MN (n =1583 at the initial examination) and African Americans from Jackson, MS (N=1854 at the initial examination). Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies. A total of 1464 non-Hipanic white participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 array (N=1345) or the Illumina Human1M-Duo or Human660W-Quad BeadChips (N=119). Imputation was performed using the single-step approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16. Genome-wide association was performed using imputed genotype dosages for nine quantitative traits related to hypertension or arteriosclerotic target-organ damage using linear mixed modeling to account for family structure. Here, genome-wide association results are reported for relative wall thickness (RWT), adjusted for age, sex, and top 10 PCs (N=1238). Please see the GENOA Study Documentation for further details. |
| The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four research networks that form the NHLBI Family Blood Pressure Program (FBPP). Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. Participants include non-Hispanic White Americans from Rochester, MN (n =1583 at the initial examination) and African Americans from Jackson, MS (N=1854 at the initial examination). Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies. A total of 1464 non-Hipanic white participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 array (N=1345) or the Illumina Human1M-Duo or Human660W-Quad BeadChips (N=119). Imputation was performed using the single-step approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16. Genome-wide association was performed using imputed genotype dosages for nine quantitative traits related to hypertension or arteriosclerotic target-organ damage using linear mixed modeling to account for family structure. Here, genome-wide association results are reported for ankle brachial index (ABI), adjusted for age and sex (N=1063). Please see the GENOA Study Documentation for further details. |
| The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four research networks that form the NHLBI Family Blood Pressure Program (FBPP). Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. Participants include non-Hispanic White Americans from Rochester, MN (n =1583 at the initial examination) and African Americans from Jackson, MS (N=1854 at the initial examination). Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies. A total of 1464 non-Hipanic white participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 array (N=1345) or the Illumina Human1M-Duo or Human660W-Quad BeadChips (N=119). Imputation was performed using the single-step approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16. Genome-wide association was performed using imputed genotype dosages for nine quantitative traits related to hypertension or arteriosclerotic target-organ damage using linear mixed modeling to account for family structure. Here, genome-wide association results are reported for urinary albumin-creatinine ratio (UACR), adjusted for age, sex, and top 10 PCs (N=1194). Please see the GENOA Study Documentation for further details. |
| The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four research networks that form the NHLBI Family Blood Pressure Program (FBPP). Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. Participants include non-Hispanic White Americans from Rochester, MN (n =1583 at the initial examination) and African Americans from Jackson, MS (N=1854 at the initial examination). Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies. A total of 1464 non-Hipanic white participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 array (N=1345) or the Illumina Human1M-Duo or Human660W-Quad BeadChips (N=119). Imputation was performed using the single-step approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16. Genome-wide association was performed using imputed genotype dosages for nine quantitative traits related to hypertension or arteriosclerotic target-organ damage using linear mixed modeling to account for family structure. Here, genome-wide association results are reported for pulse pressure, adjusted for age and sex (N=1438). Please see the GENOA Study Documentation for further details. |
| The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four research networks that form the NHLBI Family Blood Pressure Program (FBPP). Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. Participants include non-Hispanic White Americans from Rochester, MN (n =1583 at the initial examination) and African Americans from Jackson, MS (N=1854 at the initial examination). Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies. A total of 1464 non-Hipanic white participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 array (N=1345) or the Illumina Human1M-Duo or Human660W-Quad BeadChips (N=119). Imputation was performed using the single-step approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16. Genome-wide association was performed using imputed genotype dosages for nine quantitative traits related to hypertension or arteriosclerotic target-organ damage using linear mixed modeling to account for family structure. Here, genome-wide association results are reported for body mass index (BMI), adjusted for age and sex (N=1438). Please see the GENOA Study Documentation for further details. |
| The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four research networks that form the NHLBI Family Blood Pressure Program (FBPP). Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. Participants include non-Hispanic White Americans from Rochester, MN (n =1583 at the initial examination) and African Americans from Jackson, MS (N=1854 at the initial examination). Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies. A total of 1464 non-Hipanic white participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 array (N=1345) or the Illumina Human1M-Duo or Human660W-Quad BeadChips (N=119). Imputation was performed using the single-step approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16. Genome-wide association was performed using imputed genotype dosages for nine quantitative traits related to hypertension or arteriosclerotic target-organ damage using linear mixed modeling to account for family structure. Here, genome-wide association results are reported for body mass index (BMI), adjusted for age, sex, and top 10 PCs (N=1589). Please see the GENOA Study Documentation for further details. |
| The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four research networks that form the NHLBI Family Blood Pressure Program (FBPP). Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. Participants include non-Hispanic White Americans from Rochester, MN (n =1583 at the initial examination) and African Americans from Jackson, MS (N=1854 at the initial examination). Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies. A total of 1464 non-Hipanic white participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 array (N=1345) or the Illumina Human1M-Duo or Human660W-Quad BeadChips (N=119). Imputation was performed using the single-step approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16. Genome-wide association was performed using imputed genotype dosages for nine quantitative traits related to hypertension or arteriosclerotic target-organ damage using linear mixed modeling to account for family structure. Here, genome-wide association results are reported for urinary albumin-creatinine ratio (UACR), adjusted for age and sex (N=909). Please see the GENOA Study Documentation for further details. |
| The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four research networks that form the NHLBI Family Blood Pressure Program (FBPP). Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. Participants include non-Hispanic White Americans from Rochester, MN (n =1583 at the initial examination) and African Americans from Jackson, MS (N=1854 at the initial examination). Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies. A total of 1464 non-Hipanic white participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 array (N=1345) or the Illumina Human1M-Duo or Human660W-Quad BeadChips (N=119). Imputation was performed using the single-step approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16. Genome-wide association was performed using imputed genotype dosages for nine quantitative traits related to hypertension or arteriosclerotic target-organ damage using linear mixed modeling to account for family structure. Here, genome-wide association results are reported for systolic blood pressure, adjusted for age, sex, and top 10 PCs (N=1589). Please see the GENOA Study Documentation for further details. |
| The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four research networks that form the NHLBI Family Blood Pressure Program (FBPP). Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. Participants include non-Hispanic White Americans from Rochester, MN (n =1583 at the initial examination) and African Americans from Jackson, MS (N=1854 at the initial examination). Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies. A total of 1464 non-Hipanic white participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 array (N=1345) or the Illumina Human1M-Duo or Human660W-Quad BeadChips (N=119). Imputation was performed using the single-step approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16. Genome-wide association was performed using imputed genotype dosages for nine quantitative traits related to hypertension or arteriosclerotic target-organ damage using linear mixed modeling to account for family structure. Here, genome-wide association results are reported for coronary artery calcification (CAC), adjusted for age and sex (N=1043). Please see the GENOA Study Documentation for further details. |
| The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four research networks that form the NHLBI Family Blood Pressure Program (FBPP). Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. Participants include non-Hispanic White Americans from Rochester, MN (n =1583 at the initial examination) and African Americans from Jackson, MS (N=1854 at the initial examination). Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies. A total of 1464 non-Hipanic white participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 array (N=1345) or the Illumina Human1M-Duo or Human660W-Quad BeadChips (N=119). Imputation was performed using the single-step approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16. Genome-wide association was performed using imputed genotype dosages for nine quantitative traits related to hypertension or arteriosclerotic target-organ damage using linear mixed modeling to account for family structure. Here, genome-wide association results are reported for systolic blood pressure, adjusted for age and sex (N=1438). Please see the GENOA Study Documentation for further details. |
| The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four research networks that form the NHLBI Family Blood Pressure Program (FBPP). Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. Participants include non-Hispanic White Americans from Rochester, MN (n =1583 at the initial examination) and African Americans from Jackson, MS (N=1854 at the initial examination). Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies. A total of 1464 non-Hipanic white participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 array (N=1345) or the Illumina Human1M-Duo or Human660W-Quad BeadChips (N=119). Imputation was performed using the single-step approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16. Genome-wide association was performed using imputed genotype dosages for nine quantitative traits related to hypertension or arteriosclerotic target-organ damage using linear mixed modeling to account for family structure. Here, genome-wide association results are reported for diastolic blood pressure, adjusted for age, sex, and top 10 PCs (N=1589). Please see the GENOA Study Documentation for further details. |
| The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four research networks that form the NHLBI Family Blood Pressure Program (FBPP). Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. Participants include non-Hispanic White Americans from Rochester, MN (n =1583 at the initial examination) and African Americans from Jackson, MS (N=1854 at the initial examination). Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies. A total of 1464 non-Hipanic white participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 array (N=1345) or the Illumina Human1M-Duo or Human660W-Quad BeadChips (N=119). Imputation was performed using the single-step approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16. Genome-wide association was performed using imputed genotype dosages for nine quantitative traits related to hypertension or arteriosclerotic target-organ damage using linear mixed modeling to account for family structure. Here, genome-wide association results are reported for estimated glomerular filtration rate (eGFR), adjusted for age, sex, and top 10 PCs (N=1588). Please see the GENOA Study Documentation for further details. |
| The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four research networks that form the NHLBI Family Blood Pressure Program (FBPP). Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. Participants include non-Hispanic White Americans from Rochester, MN (n =1583 at the initial examination) and African Americans from Jackson, MS (N=1854 at the initial examination). Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies. A total of 1464 non-Hipanic white participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 array (N=1345) or the Illumina Human1M-Duo or Human660W-Quad BeadChips (N=119). Imputation was performed using the single-step approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16. Genome-wide association was performed using imputed genotype dosages for nine quantitative traits related to hypertension or arteriosclerotic target-organ damage using linear mixed modeling to account for family structure. Here, genome-wide association results are reported for left ventricular mass index (LVMI), adjusted for age, sex, and top 10 PCs (N=1235). Please see the GENOA Study Documentation for further details. |
| The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four research networks that form the NHLBI Family Blood Pressure Program (FBPP). Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. Participants include non-Hispanic White Americans from Rochester, MN (n =1583 at the initial examination) and African Americans from Jackson, MS (N=1854 at the initial examination). Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies. A total of 1464 non-Hipanic white participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 array (N=1345) or the Illumina Human1M-Duo or Human660W-Quad BeadChips (N=119). Imputation was performed using the single-step approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16. Genome-wide association was performed using imputed genotype dosages for nine quantitative traits related to hypertension or arteriosclerotic target-organ damage using linear mixed modeling to account for family structure. Here, genome-wide association results are reported for leukoaraiosis, adjusted for \"age, sex, and TIV\" (N=784). Please see the GENOA Study Documentation for further details. |
| The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four research networks that form the NHLBI Family Blood Pressure Program (FBPP). Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. Participants include non-Hispanic White Americans from Rochester, MN (n =1583 at the initial examination) and African Americans from Jackson, MS (N=1854 at the initial examination). Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies. A total of 1464 non-Hipanic white participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 array (N=1345) or the Illumina Human1M-Duo or Human660W-Quad BeadChips (N=119). Imputation was performed using the single-step approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16. Genome-wide association was performed using imputed genotype dosages for nine quantitative traits related to hypertension or arteriosclerotic target-organ damage using linear mixed modeling to account for family structure. Here, genome-wide association results are reported for ankle brachial index (ABI), adjusted for age, sex, and top 10 PCs (N=1242). Please see the GENOA Study Documentation for further details. |
| The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four research networks that form the NHLBI Family Blood Pressure Program (FBPP). Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. Participants include non-Hispanic White Americans from Rochester, MN (n =1583 at the initial examination) and African Americans from Jackson, MS (N=1854 at the initial examination). Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies. A total of 1464 non-Hipanic white participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 array (N=1345) or the Illumina Human1M-Duo or Human660W-Quad BeadChips (N=119). Imputation was performed using the single-step approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16. Genome-wide association was performed using imputed genotype dosages for nine quantitative traits related to hypertension or arteriosclerotic target-organ damage using linear mixed modeling to account for family structure. Here, genome-wide association results are reported for leukoaraiosis, adjusted for age, sex, TIV, and top 10 PCs (N=683). Please see the GENOA Study Documentation for further details. |
| The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four research networks that form the NHLBI Family Blood Pressure Program (FBPP). Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. Participants include non-Hispanic White Americans from Rochester, MN (n =1583 at the initial examination) and African Americans from Jackson, MS (N=1854 at the initial examination). Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies. A total of 1464 non-Hipanic white participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 array (N=1345) or the Illumina Human1M-Duo or Human660W-Quad BeadChips (N=119). Imputation was performed using the single-step approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16. Genome-wide association was performed using imputed genotype dosages for nine quantitative traits related to hypertension or arteriosclerotic target-organ damage using linear mixed modeling to account for family structure. Here, genome-wide association results are reported for estimated glomerular filtration rate (eGFR), adjusted for age and sex (N=1437). Please see the GENOA Study Documentation for further details. |
| The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four research networks that form the NHLBI Family Blood Pressure Program (FBPP). Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. Participants include non-Hispanic White Americans from Rochester, MN (n =1583 at the initial examination) and African Americans from Jackson, MS (N=1854 at the initial examination). Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies. A total of 1464 non-Hipanic white participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 array (N=1345) or the Illumina Human1M-Duo or Human660W-Quad BeadChips (N=119). Imputation was performed using the single-step approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16. Genome-wide association was performed using imputed genotype dosages for nine quantitative traits related to hypertension or arteriosclerotic target-organ damage using linear mixed modeling to account for family structure. Here, genome-wide association results are reported for diastolic blood pressure, adjusted for age and sex (N=1438). Please see the GENOA Study Documentation for further details. |
| The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four research networks that form the NHLBI Family Blood Pressure Program (FBPP). Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. Participants include non-Hispanic White Americans from Rochester, MN (n =1583 at the initial examination) and African Americans from Jackson, MS (N=1854 at the initial examination). Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies. A total of 1464 non-Hipanic white participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 array (N=1345) or the Illumina Human1M-Duo or Human660W-Quad BeadChips (N=119). Imputation was performed using the single-step approach implemented in Markov Chain Haplotyper (MaCH) 1.0.16. Genome-wide association was performed using imputed genotype dosages for nine quantitative traits related to hypertension or arteriosclerotic target-organ damage using linear mixed modeling to account for family structure. Here, genome-wide association results are reported for pulse pressure, adjusted for age, sex, and top 10 PCs (N=1589). Please see the GENOA Study Documentation for further details. |